Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 2,298 Shares

Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett sold 2,298 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $23.83, for a total value of $54,761.34. Following the transaction, the chief financial officer now owns 324,766 shares in the company, valued at approximately $7,739,173.78. This trade represents a 0.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Eva Renee Barnett also recently made the following trade(s):

• On Wednesday, January 8th, Eva Renee Barnett sold 4,105 shares of Immunovant stock. The stock was sold at an average price of $24.10, for a total transaction of $98,930.50.
• On Wednesday, November 20th, Eva Renee Barnett sold 4,174 shares of Immunovant stock. The stock was sold at an average price of $25.45, for a total transaction of $106,228.30.
• On Wednesday, November 20th, Eva Renee Barnett sold 4,174 shares of Immunovant stock. The shares were sold at an average price of $25.45, for a total transaction of $106,228.30.

Immunovant Stock Up 0.3 %

Shares of IMVT opened at $23.86 on Friday. Immunovant, Inc. has a 12 month low of $22.41 and a 12 month high of $41.38. The stock has a market cap of $3.50 billion, a price-to-earnings ratio of -10.75 and a beta of 0.66. The company has a 50-day moving average price of $26.53 and a two-hundred day moving average price of $28.50.

Immunovant (NASDAQ:IMVT) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). During the same period last year, the company posted ($0.45) earnings per share. Equities research analysts expect that Immunovant, Inc. will post -2.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IMVT has been the subject of several recent analyst reports. Bank of America decreased their target price on Immunovant from $48.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday. Oppenheimer increased their price objective on Immunovant from $47.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, October 9th. Raymond James reaffirmed an “outperform” rating and set a $36.00 target price on shares of Immunovant in a research report on Thursday, October 10th. Wells Fargo & Company reduced their price target on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Finally, Wolfe Research downgraded shares of Immunovant from an “outperform” rating to a “peer perform” rating in a report on Friday, January 3rd. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Immunovant currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

Institutional Investors Weigh In On Immunovant

Several institutional investors and hedge funds have recently made changes to their positions in the company. KBC Group NV grew its position in Immunovant by 46.2% during the 3rd quarter. KBC Group NV now owns 1,936 shares of the company’s stock worth $55,000 after acquiring an additional 612 shares during the last quarter. Assetmark Inc. boosted its stake in Immunovant by 73.8% in the third quarter. Assetmark Inc. now owns 2,891 shares of the company’s stock worth $82,000 after purchasing an additional 1,228 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Immunovant by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock worth $148,000 after purchasing an additional 934 shares during the last quarter. Bank Pictet & Cie Europe AG acquired a new stake in shares of Immunovant in the third quarter valued at $261,000. Finally, Farallon Capital Management LLC bought a new position in shares of Immunovant in the second quarter valued at about $317,000. Institutional investors and hedge funds own 47.08% of the company’s stock.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.